Neuroleptic malignant syndrome, syndrome malin
Takahashi, A.; Todoroki, J.; Murasaki, M.
Nihon Rinsho. Japanese Journal of Clinical Medicine 54(3): 839-844
1996
ISSN/ISBN: 0047-1852 PMID: 8904246 Document Number: 465564
Neuroleptic malignant syndrome (NMS) is an uncommon but serious complication of treatment with neurolepticus, made up of hyperthermia, muscular rigidity, disturbance of level of consciousness, autonomic instability and elevated serum creatine phosphokinase. Onset of NMS is often related to commencement of treatment, change of drug, or increase dose, but may occur in the absence of such an event. Physical stress has been suggested as a precipitating factor. NMS is thought to occur from central dopamine depletion in the hypothalamus and basal ganglia. In addition, it is thought that several neurotransmitters, serotonin, noradrenaline and GABA, are related in the mechanism of NMS.